EVOFEM BIOSCIENCES, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$10M
↑+34.6% +$2Mvs FY2024 (Q4)
Gross Profit
$7M
↑+24.6% +$1Mvs FY2024 (Q4)
Operating Income
$2M
↓-51.0% -$3Mvs FY2024 (Q4)
Net Income
$2M
↓-55.1% -$2Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $10M | $7M |
| COGS | $3M | $2M |
| Gross Profit | $7M | $6M |
| R&D | $0 | $649K |
| SG&A | $0 | $0 |
| D&A | $5K | $5K |
| Other OpEx | $5M | $0 |
| Operating Income | $2M | $5M |
| Interest Exp. | $455K | $570K |
| Other Non-Op | $0 | $0 |
| Pretax Income | $2M | $4M |
| Tax | $6K | $0 |
| Net Income | $2M | $4M |
QuarterCharts · SEC EDGAR data · EVFM · Comparing FY2025 (Q4) vs FY2024 (Q4)